Evidence Omega 3 DHA may improve the outcome of some chemotherapies
Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial
P Bougnoux,1,2* N Hajjaji,1,2 M N Ferrasson,1,2 B Giraudeau,3 C Couet,1,4 and O Le Floch1,2
http://www.ncbi.nlm.nih.gov/pmc/arti...6/?tool=pubmed
"
Several research groups, including ours, have shown that docosahexaenoic acid (DHA), a lipid of marine algal origin mainly provided by diet, has, experimentally, the ability to increase the efficacy of anti-cancer agents."
"As DHA incorporates into cell membranes, this differential handling of ROS may account for the selectivity of DHA-induced tissue sensitisation by anti-cancer agents in tumour tissues compared with non-tumour tissues. Along this line, the lack of additional toxicity in non-tumour tissues has been consistently documented under conditions in which tumour tissue DHA was sensitised to chemotherapy (Hardman et al, 1999; Kato et al, 2002; Germain et al, 2003; Xue et al, 2007) or radiation therapy (Wen et al, 2003) in rodents.
On the basis of these results, we conducted a pilot phase II clinical trial in metastatic breast cancer patients to investigate the efficacy and safety of adding DHA to an ROS-generating chemotherapy regimen, that is an anthracycline-based regimen (FEC). We found that the combination was safe while retaining significant anti-tumour activity in the sub-population of patients with high plasma DHA incorporation, suggesting that DHA has a potential to specifically chemosensitise tumours."
Threaded Mode